NR1H4 and Wilson disease: These findings indicated that in comparison with BSH‐resistant GlyMCA, oral TβMCA is insufficient to alleviate gut FXR‐associated metabolic abnormalities[7, 8] and bile cholesterol supersaturation after a WD.